Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 20

1.

JNCI and cancer prevention.

Dunn BK, Ghosh S, Kramer BS.

J Natl Cancer Inst. 2015 Feb 24;107(3). pii: djv021. doi: 10.1093/jnci/djv021. Print 2015 Mar.

2.

A tale of two trials: The impact of 5α-reductase inhibition on prostate cancer (Review).

Lacy JM, Kyprianou N.

Oncol Lett. 2014 Oct;8(4):1391-1396. Epub 2014 Jul 28.

3.

Androgens and prostate disease.

Cooper LA, Page ST.

Asian J Androl. 2014 Mar-Apr;16(2):248-55. doi: 10.4103/1008-682X.122361. Review.

4.

The strategies to control prostate cancer by chemoprevention approaches.

Ting H, Deep G, Agarwal C, Agarwal R.

Mutat Res. 2014 Feb;760:1-15. doi: 10.1016/j.mrfmmm.2013.12.003. Epub 2014 Jan 2. Review.

5.

Utility of 5-alpha-reductase inhibitors in active surveillance for favourable risk prostate cancer.

Chiang AS, Loblaw DA, Jethava V, Sethukavalan P, Zhang L, Vesprini D, Mamedov A, Nam R, Klotz L.

Can Urol Assoc J. 2013 Nov-Dec;7(11-12):450-3. doi: 10.5489/cuaj.262.

6.

Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study.

Robinson D, Garmo H, Bill-Axelson A, Mucci L, Holmberg L, Stattin P.

BMJ. 2013 Jun 18;346:f3406. doi: 10.1136/bmj.f3406.

7.

Selenium and prostate cancer prevention: insights from the selenium and vitamin E cancer prevention trial (SELECT).

Nicastro HL, Dunn BK.

Nutrients. 2013 Apr 3;5(4):1122-48. doi: 10.3390/nu5041122. Review.

8.

A multiscale, mechanism-driven, dynamic model for the effects of 5α-reductase inhibition on prostate maintenance.

Zager MG, Barton HA.

PLoS One. 2012;7(9):e44359. doi: 10.1371/journal.pone.0044359. Epub 2012 Sep 6.

9.

Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials.

Pinsky PF, Black A, Grubb R, Crawford ED, Andriole G, Thompson I, Parnes H.

Cancer. 2013 Feb 1;119(3):593-601. doi: 10.1002/cncr.27774. Epub 2012 Aug 14.

10.

Associations of serum sex steroid hormone and 5α-androstane-3α,17β-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride.

Kristal AR, Till C, Tangen CM, Goodman PJ, Neuhouser ML, Stanczyk FZ, Chu LW, Patel SK, Thompson IM, Reichardt JK, Hoque A, Platz EA, Figg WD, Van Bokhoven A, Lippman SM, Hsing AW.

Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1823-32. doi: 10.1158/1055-9965.EPI-12-0695. Epub 2012 Aug 9.

11.

Epidemiology of prostate cancer and treatment remarks.

Arcangeli S, Pinzi V, Arcangeli G.

World J Radiol. 2012 Jun 28;4(6):241-6. doi: 10.4329/wjr.v4.i6.241.

12.

Does variation in either age at start of therapy or duration of therapy make chemoprevention with finasteride cost-effective?

Stewart SB, Scales CD Jr, Moul JW, Reed SD.

Prostate Cancer Prostatic Dis. 2012 Dec;15(4):380-5. doi: 10.1038/pcan.2012.26. Epub 2012 Jul 10.

13.

Chemoprevention of prostate cancer: Natural compounds, antiandrogens, and antioxidants - In vivo evidence.

Ozten-Kandaş N, Bosland MC.

J Carcinog. 2011;10:27. doi: 10.4103/1477-3163.90438. Epub 2011 Nov 30.

14.

Transition of a clinical trial into translational research: the prostate cancer prevention trial experience.

Goodman PJ, Tangen CM, Kristal AR, Thompson IM, Lucia MS, Platz EA, Figg WD, Hoque A, Hsing A, Neuhouser ML, Parnes HL, Reichardt JK, Santella RM, Till C, Lippman SM.

Cancer Prev Res (Phila). 2010 Dec;3(12):1523-33. doi: 10.1158/1940-6207.CAPR-09-0256.

15.

Prevention strategies in prostate cancer.

Trottier G, Lawrentschuk N, Fleshner NE.

Curr Oncol. 2010 Sep;17 Suppl 2:S4-10.

16.

Novel targets for prostate cancer chemoprevention.

Sarkar FH, Li Y, Wang Z, Kong D.

Endocr Relat Cancer. 2010 Aug 16;17(3):R195-212. doi: 10.1677/ERC-10-0074. Print 2010 Sep. Review.

17.

Gleason grading controversies: what the chemoprevention trials have taught us.

Klotz L, Drachenberg D, Fradet Y, Saad F, Trachtenberg J, Zlotta A.

Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S115-20.

18.

Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.

Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ, Ballentine Carter H, Costantino JP, Epstein JI, Godley PA, Harris RP, Wilt TJ, Wittes J, Zon R, Schellhammer P; American Society of Clinical Oncology Health Services Committee; American Urological Association Practice Guidelines Committee.

J Clin Oncol. 2009 Mar 20;27(9):1502-16. doi: 10.1200/JCO.2008.16.9599. Epub 2009 Feb 24. Review. Erratum in: J Clin Oncol. 2009 Jun 1;27(16):2742.

19.

Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

Winer E, Gralow J, Diller L, Karlan B, Loehrer P, Pierce L, Demetri G, Ganz P, Kramer B, Kris M, Markman M, Mayer R, Pfister D, Raghavan D, Ramsey S, Reaman G, Sandler H, Sawaya R, Schuchter L, Sweetenham J, Vahdat L, Schilsky RL; American Society of Clinical Oncology.

J Clin Oncol. 2009 Feb 10;27(5):812-26. doi: 10.1200/JCO.2008.21.2134. Epub 2008 Dec 22. Erratum in: J Clin Oncol. 2009 Jun 20;27(18):3070-1.

20.

American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment.

Zon RT, Goss E, Vogel VG, Chlebowski RT, Jatoi I, Robson ME, Wollins DS, Garber JE, Brown P, Kramer BS; American Society of Clinical Oncology.

J Clin Oncol. 2009 Feb 20;27(6):986-93. doi: 10.1200/JCO.2008.16.3691. Epub 2008 Dec 15.

Items per page

Supplemental Content

Write to the Help Desk